Different anthracycline derivates for reducing cardiotoxicity in cancer patients

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Van Dalen, Elvira C ^a   Michiels, E M C ^b   Caron, H N ^b   Kremer, L C M ^b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN;

ALOPECIA; ANEMIA; ASTHENIA; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG FEVER; EMBASE; FATIGUE; HEART FAILURE; HUMAN; INFECTION; KIDNEY DISEASE; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MEDLINE; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT RESPONSE;

EID: 42749100219     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005006.pub2     Document Type: Review

References (84)

1. Batist G, Ramakriskan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. Journal of Clinical Oncology 2001;19:1444-54.
2. Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treatment Reports 1986;70:261-6.
3. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of Oncology 2004;15:1527-34.
4. French Epirubicin Study Group. A prospective randomized pahase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. Journal of Clinical Oncology 1988;6:679-88.
5. Gasparini G, Dal Fior S, Panizzoni GA, Favretto S, Pozza F. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer, a randomized clinical trial. American Journal of Clinical Oncology 1991;14:38-44.
6. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36.
7. Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide v fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Journal of Clinical Oncology 1988;6:976-82.
8. Mouridsen HT, Somers R, Santoro A, Mulder JH, Bramwell V, van Oosterom AT, et al. Doxorubicin vs epirubicin in advanced soft tissue sarcomas, an EORTC randomized phase II study. Bonadonna G (ed) Advances in anthracycline chemotherapy: epirubicin, Masson, Milan 1984:95-103.
9. Al-Ismael DAD, Whittaker JA, Gouch J. Combination chemotherapy including epirubicin for the amnagement of non-hodgkin's lymphoma. European Journal of Cancer and Clinical Oncology 1987;23:1379-84.
10. Armand JP. Bonadonna G (ed) Phase II and phase III studies with epirubicin in breast cancer in France. Advances in anthracycline chemotherapy: epirubicin. Masson, Milan: 75-82, 1984.
11. Aviles A, Arevila N, Diaz Maqueo JC, Gomez T, Garcia R, Jesus Nambo MA. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leukemia and Lymphoma 1993;11:275-9.
12. Aviles A, Soto B, Guzman R, Garcia EL, Jesus Nambo M, Diaz-Maqueo JC. Results of a randomized study of early stage hodgkin's disease using ABVD, EBVD, or MBVD. Medical and Pediatric Oncology 1995;24:171-5.
13. Baldini E, Gardin G, Evangelista G, Prochilo T, Collecchi P, Lionetti R. Long-term results of combined modality therapy for inflammatory breast carcinoma. Clinical Breast Cancer 2004;5:358-63.
14. Benjamin RS, Mason J, Billingham ME. Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy. Cancer Treatment Reports 1978;62:935-9.
15. Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, et al. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A=doxorubicin) vs VICOP-B (I=idarubicin). Haematologica 1997;82:309-13.
16. Bezwoda WR. Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide. Medical and Pediatric Oncology 1986;14:26-9.
17. Bhutani M, Kumar L, Vora A, Bhardwaj N, Kumar Pathak A, Singh R, et al. Randomized study comparing 4'-epi-doxorubicin (epirubicin) versus doxorubicin as a part of induction treatment in adult acute lymphoblastic leukemia. American Journal of Hematology 2002;71:241-7.
18. Bonadonna G, Brambilla C, Rossi A, Bonfante V, Ferrari L, Crippa F, et al. Epirubicin in advanced breast cancer, the experience of the Milan Cancer Institute. Bonadonna G (ed) Advances in anthracycline chemotherapy: epirubicin, Masson, Milan 1984:63-70.
19. Bonfante V, Ferrari L, Brambilla C, Rossi A, Villani F, Crippa F, et al. New anthracycline analogs in advanced breast cancer. European Journal of Cancer and Clinical Oncology 1986;22:1379-85.
20. Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, et al. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. British Journal of Cancer 1998;77:2257-63.
21. Brugiatelli M, Federico M, Gobbi PG, Avanzini P, Callea V, Cavanna L, et al. Epidoxorubixin vs idarubicin containing regemines in intermediate and high grade non-hodgkin's lymphoma: preliminary results of a multicentric randomized trial. Haematologica 1993;78:306-12.
22. Burton C, Smith P, Vaughan-Hudson G, Qian W, Hoskin P, Cunningham D, et al. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. British Journal of Hematology 2005;130:536-41.
23. Casper ES. The cardiotoxic effect of epirubicin and doxorubicin (adriamycin), a clinical and radionuclide cine-angiographic comparison. Clinical Trials Journal 1987;24:57-67.
24. Casper ES. Epirubicin and doxorubicin in advanced breast cancer, a comparative evaluation of epirubicin and doxorubicin. Clinical Trials Journal 1987;24:139-41.
25. Cottin Y, Touzery C, Dalloz F, Coudert B, Toubeau M, Riedinger A, et al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evalution of the diastolic and systolic parameters studied by radionuclide angiography. Clinical Cardiology 1998;21:665-70.
26. Creutzig U, Hofmann J, Ritter J, Schellong G. [Therapierealisierung und komplikationen in der therapiestudie BFM-83 fur die akute myeloische leukamie]. Klinische Padiatrie 1988;200:190-9.
27. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Blutters Sawatzki D, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia 2001;15:348-54.
28. Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, et al. [Verbesserung der prognose bei kindernmit AML: ergebnisse der studie AML-BFM 93]. Klinische Padiatrie 2001;213:175-85.
29. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study acute myeloid leukemia-berlin-frankfurt-munster 93. Journal of Clinical Oncology 2001;19:2705-13.
30. De Lena M, Colucci G, Marzullo F, Lorusso V, Brandi M. Randomized trial with two CHOP-B regimens (with doxorubicin or epirubicin) in poor prognosis non-hodgkin's lymphomas. Clinical Trials Journal 1987;24:223-9.
31. De Lena M, Maiello E, Lorusso V, Brandi M, Calabrese P, Romito S, et al. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-hodgkin's lymphomas, a randomized trial. Medical Oncology & Tumor Pharmacotherapy 1989;6:163-9.
32. Federico M, Clo V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, et al. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced agressive non-hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800-11.
33. Gebbia V, Blasi L, Borsellino N, Caruso M, Leonardi V, Agostara B, et al. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomized phase II study. Anticancer Research 2003;23:765-72.
34. Gregory RK, Hill ME, Moore J, A'Hern RP, Johnston SRD, Blake P, et al. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. European Journal of Cancer 2000;36:503-7.
35. Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, et al. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 1990;13:24-7.
36. Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, et al. Prognostic subgroups: the key factor for treatment outcome in metastatic breast cancer, results of a three-arm randomized multicenter trial comparing doxorubicin, epirubicin and mitoxantrone each in combination with cyclophosphamide. Onkologie 1993;16:344-53.
37. Hernadi Z, Juhasz B, Poka R, Lampe LG. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4-epi-doxorubicin in the treatment of advanced ovarian cancer. International Journal of Gynecology and Obstetrics 1988;27:199-204.
38. Homesley HD, Harry DS, O'Toole RV, Hoogstraten B, Franklin EW, Cavanagh D, et al. Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. American Journal of Clinical Oncology 1992;15:129-34.
39. Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. American Journal of Clinical Oncology 1989;12:57- 62.
40. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. Journal of Clinical Oncology 1985;3:818-26.
41. Keiling R, Armand PP, Hurteloup P, Cappelaere P. [Die franzosische FAC-vs-FEC-studie bei fortgeschrittenen mammakarzinomen]. Onkologie 1986;9:8-10.
42. Klener P, Donner L, Kozena J. Daunorubicin and adriamycin in the treatment of leukemia. Neoplasma 1973;20:87-96.
43. Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E. Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. European Journal of Haematology 1991;46:301-5.
44. Lawton PA, Spittle MF, Ostrowski MJ, Young T, Madden F, Folkes A, et al. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clinical Oncology 1993;5:80-4.
45. Lopez M, Papaldo P, Di Lauro L, Vici P, Carpano S, Conti EMS. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 1989;46:1-5.
46. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia, a multicentric study from the italian co-operative group GIMEMA. European Journal of Cancer 1991;27:750-5.
47. Maung K. Pegylated liposomal doxorubicin (doxil) versus doxorubicin for first-line treatment of metastatic breast cancer. Clinical Breast Cancer 2002:183-4.
48. Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas, a randomized phase II / phase III study of the EORTC soft tissue and bone sarcoma group. European Journal of Cancer & Clinical Oncology 1987;23:1477- 83.
49. Nair R, Ramakrishnan G, Nair NN, Saikia TK, Parikh PM, Joshi SR, et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-hodgkin's lymphoma. Cancer 1998;82:2282-88.
50. Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, de Gislain C, Pouillart P, et al. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. European Journal of Cancer 2001;37:1132-40.
51. Neri B, Cini-Neri G, Bandinelli M, Pacini P, Bartalucci S, Ciapini A. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects. International Journal of Clinical Pharmacology, Therapy and Toxicology 1989;27:217-21.
52. Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas, a study of the EORTC soft tissue and bone sarcoma group. British Journal of Cancer 1998;78:1634-39.
53. Nielsen OS, Dombernowsky P, Mouridsen H, Daugaard S, van Glabbeke M, Kirkpatrick A, et al. Epirubicine is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas, the experience of the EORTC soft tissue and bone sarcoma group. Sarcoma 2000;4:31-5.
54. Nikkanen TAV, Jakobsson M, Jarvinen M, Liipo K, Ojala A, Paloheimo S, et al. Doxorubicin and 4'epidoxorubicin in combination chemotherapy of extensive small cell lung cancer. Acta Oncologica 1988;27:75-6.
55. O'Brian MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trials of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus concentional doxorubicin for the first-line treatment of metastatic breast cancer. Annals of Oncology 2004;15:440-9.
56. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. Journal of Clinical Oncology 1991;9:2148-52.
57. Pinedo HM, Mouridsen HT, Somers R, Santor A, Mulder YH, Blanwell V, et al. A ransomized trial comparing the effects of epirubicin and doxorubicin in soft tissue sarcoma. Clinical Trials Journal 1987;24:231-41.
58. Sculier JP, Bureau G, Giner V, Thiriaux J, MIchel J, Berchier MC, et al. Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the european lung cancer working party. Seminars in Oncology 1995;22:18-22.
59. Smith AP, Anderson EG, Chappell AG. Epirubicin and small cell lung cancer, a pilot study of the efficacy and toxicity of epirubicin and doxorubicin (adriamycin). Clinical Trials Journal 1987;24:195-200.
60. Suzuki T, Yamamoto H, Iwasaki T, Okamoto S, Iizuka T, Kanda H, et al. A comparative study of 4'epi-doxorubicin and doxorubicin cardiotoxicities. Japanese Journal of Cancer Chemotherapy 1984;11:2170-76.
61. Tanaka T, Suzuki K, Ota M, Hiyoshi Y, Yoshioka F, Kato H. Effects of adriamycin and daunomycin on cardiac function. Japanese Journal of Cancer Chemotherapy 1983;10:2393-98.
62. Toda K, Asaishi K, Okazaki M, Okazaki Y, Okazaki A, Sato H, et al. Intra-arterial infusion chemotherapy for advanced breast cancer-effects and side effects of adriamycin, 4'-epi-adriamycin and THP-adriamycin. Japanese Journal of Cancer & Chemotherapy 1989;16:3011-14.
63. Tsushima K, Sakata Y, Suzuki H, Saitoh S, Sugimoto N, Itoh T, et al. A randomized controlled study of 5-fluorouracil / doxorubicin / mitomycin C / OK-432 (FAM-OK) therapy and 5-flourouracil / epirubicin /mitomycin C/ OK-432 (FEM-OK) therapy in advanced gastric cancer. Journal of the Japanese Society for Cancer Therapy 1991;26:1317-24.
64. Yates J, Glidewell O, Wiernik P, Cooper M R, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60:454-62.
65. Zinzani PL, Martelli M, Storti S, Musso M, Cantonetti M, Leone G, et al. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-hodgkin's lymphoma. Leukemia and Lymphoma 1995;19:329-35.
66. Doxorubicin in treating patients with AIDS-related Kaposi's sarcoma. Ongoing study November 1996.
67. Combination chemotherapy after surgery in treating patients with stage I, stage II, or stage III breast cancer. Ongoing study Nm.
68. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Reports 1978;62:865-72.
69. Bonadonna G, Monfardini S. Cardiac toxicity of daunorubicin. Lancet 1969;1:837.
70. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester (UK): John Wiley & Sons Ltd.
71. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline induced clinical heart failure in a cohort of 607 children: a long-term follow-up study. Journal of Clinical Oncology 2001;19(1):191-6.
72. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology 2002;13:819-29.
73. Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Annals of Oncology 2002;13:503-12.
74. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
75. Meinardi MT, Van der Graaf WTA, Gietema JA, Van den Berg MP, Sleijfer DT, De Vries EGE, et al. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart 2002;88:81-2.
76. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
77. Muggia FM, Green MD. New anthracycline antitumor antibiotics. Critical Reviews in Oncology/Hematology 1991;11:43-64.
78. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Seminars in Oncology 2006;33:2-14.
79. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. British Journal of Cancer 2002;86:1697-1700.
80. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
81. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
82. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Annals of Internal Medicine 1996;125:47-58.
83. Simbre II VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy, implications for children. Pediatric Drugs 2005;7:187-202.
84. WHO Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.